The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, latest, MyelomaJuly 9, 2024
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, MyelomaDecember 8, 2023
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
MPE launches the Myeloma and AL Amyloidosis European Clinical Trial NavigatorAccess, AL amyloidosis, MPE, MyelomaApril 23, 2024
European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, CAR-T, MyelomaApril 23, 2024
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosisJanuary 17, 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, MyelomaMarch 31, 2021
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
